Our website uses cookies which are small bits of data stored as text files on your device. We use these cookies as described in our cookie policy. You can disable or change your cookie settings at any time but parts of our site will not function correctly without them.

Logos for IncyteCARES Connecting to Access, Reimbursement, Education and Support & Jakafi (ruxolitinib) tablets

IncyteCARES for Jakafi is a program for residents
of the United States and Puerto Rico.

Home Healthcare Professionals IncyteCARES for Jakafi Home Financial Assistance Options

Financial Assistance
Support and
Information
for Your Patients

graphic of 2 different hands holding a savings card graphic of 2 different hands holding a savings card graphic of 2 different hands holding a savings card

Healthcare Professionals

Enroll a Patient
savings card icon

For Eligible Patients With Commercial Prescription Insurance
IncyteCARES for Jakafi Savings Program

Eligible patients can receive their medication for as little as $0 per month, subject to monthly and annual limits*

Image of Patient Savings Card

To qualify, patients must:

  • Have commercial prescription drug coverage. Patients insured under federal or state government prescription drug programs—including Medicare Part D, Medicare Advantage, Medicaid, or TRICARE—are not eligible. Patients without prescription drug coverage are also not eligible
  • Be a resident of the United States or Puerto Rico
  • Have a valid prescription for an Incyte medication for an FDA-approved use

*Uninsured, cash-paying patients are not eligible. Not valid for patients insured through Medicare Part D, Medicare Advantage, Medicaid, and TRICARE, or any state medical or pharmaceutical assistance program. A monthly and yearly maximum benefit applies. Limit one 30-day supply per 30 days. Valid prescription for Jakafi® (ruxolitinib) for an FDA-approved indication or compendia-recognized use is required. Please see full criteria for eligibility or call IncyteCARES for Jakafi at 1-855-452-5234. Update effective as of March 1, 2023.

How to enroll your patients:

Option 1: Enroll your patient in IncyteCARES for Jakafi.

We’ll do the rest. As part of our introductory call, we inform all newly enrolled patients about the IncyteCARES for Jakafi Savings Program and help eligible patients to apply for it.

Option 2: Complete an application at IncyteCAREScopay.com.

Once you submit the application, a patient membership number is immediately issued and ready to use. We will send the patient a welcome letter and a savings card that shows their membership number. Your patient does not need to enroll in IncyteCARES for Jakafi to be eligible for a savings card.

For more information, call IncyteCARES for Jakafi at 1-855-452-5234, Monday through Friday, 8 am–8 pm ET.

Hand and Rx symbol

For Eligible Patients Who Are Uninsured or Underinsured for Jakafi® (ruxolitinib)
IncyteCARES for Jakafi Patient Assistance Program

Eligible patients can receive Jakafi free of charge†

The IncyteCARES for Jakafi Patient Assistance Program (PAP) helps eligible patients who do not have prescription drug insurance or who have trouble affording their out-of-pocket costs for Jakafi. No purchase contingencies or other obligations apply.

To qualify, patients must:

  • Be confirmed as eligible for and enrolled in IncyteCARES for Jakafi
  • Be a resident of the United States or Puerto Rico
  • Have a valid prescription for an Incyte medication for an FDA-approved use
  • Meet one of these 3 criteria:

    Uninsured

    1. Have no prescription drug coverage and meet household income criteria

      2. Underinsured

    2. Have Medicare Part D and meet household income criteria and additional program requirements
    3. Have any other type of prescription drug insurance (commercial, Medicaid, etc) but have exhausted or been denied coverage for Jakafi and meet household income criteria

How to enroll your patients:

First, you must enroll your patient in IncyteCARES for Jakafi.

You can provide their required income information on the IncyteCARES for Jakafi enrollment form to start the process. Or we can explain the program and gather their income information during the introductory call we make to all patients newly enrolled in IncyteCARES for Jakafi.

Within 2 business days, patients are notified of "conditional approval," which allows them to receive free medication for 90 days. Full approval is only granted once income information is submitted and confirmed.

†Terms and conditions apply. Terms of this program may change at any time.

clock icon

For Patients Whose Insurance Coverage Approval Is Delayed
IncyteCARES for Jakafi Temporary Access Program

Eligible patients receive a free short-term supply of Jakafi‡

If a patient’s prescription drug insurer requires more than a 3-day wait for determining coverage approval, we may be able to provide a free 30-day supply of the prescribed Incyte medication in the meantime. No purchase contingencies or other obligations apply.

To qualify, patients must:

  • Be confirmed as eligible for and enrolled in IncyteCARES for Jakafi
  • Have commercial prescription drug coverage or a healthcare exchange plan. Patients insured under federal or state government prescription drug programs—including Medicare Part D, Medicare Advantage, Medicaid, or TRICARE—are not eligible. Patients without prescription drug coverage are also not eligible
  • Be a resident of the United States or Puerto Rico
  • Have a valid prescription for an Incyte medication for an FDA-approved use
  • Provide proof of the coverage delay. This may be a notice you or your patient receive from the insurance company

To learn more:

Call IncyteCARES for Jakafi at 1-855-452-5234, Monday through Friday, 8 am–8 pm ET.

‡Terms and conditions apply. Terms of this program may change at any time.

information icon

For Patients Covered by Any Type of Insurance or Without Insurance
Information About Nonprofit or Other Support Organizations

Patients may be eligible for help with medication, treatment-related travel, and other costs

If your patients do not qualify for our IncyteCARES for Jakafi Savings Program or Patient Assistance Program, we may be able to provide information about other organizations or independent foundations that may offer help. Some assist with medication costs, transportation or lodging expenses related to treatment, or counseling services, offered at reduced or no cost. Eligibility and availability of these assistance programs are determined by the individual organizations.

To learn more:

Call IncyteCARES for Jakafi at 1-855-452-5234, Monday through Friday, 8 am–8 pm ET.

INDICATIONS AND USAGE

Jakafi is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.

Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.

Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.

Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

IMPORTANT SAFETY INFORMATION

  • Treatment with Jakafi® (ruxolitinib) can cause thrombocytopenia, anemia and neutropenia, which are each dose-related effects. Perform a pre-treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated
  • Manage thrombocytopenia by reducing the dose or temporarily interrupting Jakafi. Platelet transfusions may be necessary
  • Patients developing anemia may require blood transfusions and/or dose modifications of Jakafi
  • Severe neutropenia (ANC <0.5 x 109/L) was generally reversible by withholding Jakafi until recovery
  • Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting Jakafi until active serious infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly. Use active surveillance and prophylactic antibiotics according to clinical guidelines.
  • Tuberculosis (TB) infection has been reported. Observe patients taking Jakafi for signs and symptoms of active TB and manage promptly. Prior to initiating Jakafi, evaluate patients for TB risk factors and test those at higher risk for latent infection. Consult a physician with expertise in the treatment of TB before starting Jakafi in patients with evidence of active or latent TB. Continuation of Jakafi during treatment of active TB should be based on the overall risk-benefit determination
  • Progressive multifocal leukoencephalopathy (PML) has occurred with Jakafi treatment. If PML is suspected, stop Jakafi and evaluate
  • Herpes zoster infection has been reported in patients receiving Jakafi. Advise patients about early signs and symptoms of herpes zoster and to seek early treatment. Herpes simplex virus reactivation and/or dissemination has been reported in patients receiving Jakafi. Monitor patients for the development of herpes simplex infections. If a patient develops evidence of dissemination of herpes simplex, consider interrupting treatment with Jakafi; patients should be promptly treated and monitored according to clinical guidelines
  • Increases in hepatitis B viral load with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic hepatitis B virus (HBV) infections. Monitor and treat patients with chronic HBV infection according to clinical guidelines
  • When discontinuing Jakafi, myeloproliferative neoplasm-related symptoms may return within one week. After discontinuation, some patients with myelofibrosis have experienced fever, respiratory distress, hypotension, DIC, or multi-organ failure. If any of these occur after discontinuation or while tapering Jakafi, evaluate and treat any intercurrent illness and consider restarting or increasing the dose of Jakafi. Instruct patients not to interrupt or discontinue Jakafi without consulting their physician. When discontinuing or interrupting Jakafi for reasons other than thrombocytopenia or neutropenia, consider gradual tapering rather than abrupt discontinuation
  • Non-melanoma skin cancers (NMSC) including basal cell, squamous cell, and Merkel cell carcinoma have occurred. Perform periodic skin examinations
  • Treatment with Jakafi has been associated with increases in total cholesterol, low-density lipoprotein cholesterol, and triglycerides. Assess lipid parameters 8-12 weeks after initiating Jakafi. Monitor and treat according to clinical guidelines for the management of hyperlipidemia
  • Another JAK-inhibitor has increased the risk of major adverse cardiovascular events (MACE), including cardiovascular death, myocardial infarction, and stroke (compared to those treated with tumor TNF blockers) in patients with rheumatoid arthritis, a condition for which Jakafi is not indicated. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with Jakafi particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur
  • Another JAK-inhibitor has increased the risk of thrombosis, including deep venous thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which Jakafi is not indicated. In patients with myelofibrosis (MF) and polycythemia vera (PV) treated with Jakafi in clinical trials, the rates of thromboembolic events were similar in Jakafi and control treated patients. Patients with symptoms of thrombosis should be promptly evaluated and treated appropriately
  • Another JAK-inhibitor has increased the risk of lymphoma and other malignancies excluding NMSC (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which Jakafi is not indicated. Patients who are current or past smokers are at additional increased risk. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with Jakafi, particularly in patients with a known secondary malignancy (other than a successfully treated NMSC), patients who develop a malignancy, and patients who are current or past smokers
  • In myelofibrosis and polycythemia vera, the most common nonhematologic adverse reactions (incidence ≥15%) were bruising, dizziness, headache, and diarrhea. In acute graft-versus-host disease, the most common nonhematologic adverse reactions (incidence >50%) were infections (pathogen not specified) and edema. In chronic graft-versus-host disease, the most common nonhematologic adverse reactions (incidence >20%) were infections (pathogen not specified) and viral infections
  • Avoid concomitant use with fluconazole doses greater than 200 mg. Dose modifications may be required when administering Jakafi with fluconazole doses of 200 mg or less, or with strong CYP3A4 inhibitors, or in patients with renal or hepatic impairment. Patients should be closely monitored and the dose titrated based on safety and efficacy
  • Use of Jakafi during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus. Women taking Jakafi should not breastfeed during treatment and for 2 weeks after the final dose

Please see Full Prescribing Information for Jakafi.